Low doses of ketazolam in <font color="red">anxiety_2</font> <font color="red">:_2</font> a double - blind , placebo - controlled study . 
<br>
<br> A multicenter , double - blind , between - patient trial comparing two doses of ketazolam ( 15 and 30 mg ) with placebo , each given once daily , in the evening , to 92 outpatients affected by <font color="red">generalized_1</font> <font color="red">anxiety_2</font> <font color="red">disorders_1</font> for at least 1 month , was carried out . After 1-week washout period 47 patients were randomized to ketazolam 15 mg , and 45 to placebo for 15 days ( first period ) . At the end of this period , if the patient experienced a <font color="red">decrease_1</font> <font color="red">on_1</font> <font color="red">the_1</font> <font color="red">total_1</font> <font color="red">Hamilton_1</font> <font color="red">Anxiety_1</font> <font color="red">Rating_1</font> <font color="red">Scale_1</font> <font color="red">(_1</font> <font color="red">HAM_1</font> <font color="red">-_1</font> <font color="red">A_1</font> <font color="red">)_1</font> of at least 25% of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of ketazolam were added to the previous treatment ( second period ) . <font color="red">Anxiety_2</font> was rated after 2 and 4 weeks with the <font color="red">Italian_1</font> <font color="red">HAM_1</font> <font color="red">-_1</font> <font color="red">A_1</font> <font color="red">scale_1</font> and with a <font color="red">4-point_1</font> <font color="red">scale_1</font> <font color="red">(_1</font> <font color="red">patient_1</font> <font color="red">'s_1</font> <font color="red">assessment_1</font> <font color="red">)_1</font> <font color="red">._1</font> Seventy - eight patients completed the first period and 75 the whole study . During the first period the <font color="red">percentage_1</font> <font color="red">of_1</font> <font color="red">responders_1</font> was almost identical in both treatment groups , but during the second period a further <font color="red">slight_1</font> <font color="red">improvement_1</font> was observed in the early placebo responders , while the <font color="red">HAM_2</font> <font color="red">-_2</font> <font color="red">A_2</font> <font color="red">score_2</font> of patients on ketazolam continued to <font color="red">improve_1</font> <font color="red">significantly_1</font> ( p less than 0.01 ) throughout the study . Likewise a significant ( p less than 0.001 ) difference between treatments was observed , on the <font color="red">4-point_1</font> <font color="red">scale_1</font> <font color="red">,_1</font> in the population as a whole ( end of first period ) as well as in responder patients ( end second period ) . <font color="red">Tolerability_3</font> was good , except in 1 patient on placebo , who was withdrawn from the study because of <font color="red">severe_1</font> <font color="red">headache_2</font> <font color="red">._2</font>